SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.
The Hepatocellular Carcinoma Immunotherapy Guideline Expert Panel was formed to generate consensus recommendations pertaining to the treatment of patients with hepatocellular carcinoma (HCC). Recently, the checkpoint inhibitor atezolizumab was approved by the U.S. FDA in combination with the anti-VEGF therapy bevacizumab as a first-line treatment for HCC. Additional immunotherapies targeting the PD-(L)-1 axis are approved second-line options. Ongoing trials are evaluating additional immunotherapeutic strategies for this disease state. Reflecting the evolving therapeutic landscape, SITC is currently developing an HCC CPG with topics including selection of appropriate immunotherapeutic regimens, recognition and management of adverse events, and patient quality of life considerations.
Published September 12, 2021 in the Journal for ImmunoTherapy of Cancer (JITC) as "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma"
In this introductory webinar, Expert Panel members provide attendees with an overview of the published guideline and highlight selected recommendations that are applicable to some of the most common scenarios clinicians may encounter while treating their patients with immunotherapy. After attending this webinar, learners will be better able to implement immunotherapy treatments effectively and in accordance with the recommendations in the SITC CPG. CME, CNE and CPE credits are available.
This advanced webinar is designed so that attendees will know how to appraise and classify organ-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease.This webinar is not accredited.
Ignacio Melero, MD, PhDFoundation for Applied Medical Research (FIMA)
Ghassan K. Abou-Alfa, MD, MBA – Memorial Sloan Kettering Cancer Center
Ann Lii-Cheng, MD, PhD – National Taiwan University Hospital
Austin G. Duffy, MD – The Mater Hospital/University College Dublin
Anthony B. El-Khoueiry, MD – University of Southern California
Richard S. Finn, MD – David Geffen School of Medicine, University of California Los Angeles
Peter R. Galle, MD – University of Mainz Medical Center
Lipika Goyal, MD – Massachusetts General Hospital
Aiwu Ruth He, MD – Georgetown University Medical Center
Ahmed O. Kaseb, MD – The University of Texas MD Anderson Cancer Center
Robin Kate Kelley, MD – UCSF Helen Diller Family Comprehensive Care Center
Riccardo Lencioni, MD – University of Pisa Medical Center
Amaia Lujambio, PhD – Icahn School of Medicine at Mount Sinai
Donna Mabry Hrones, NP – National Institutes of Health
David J. Pinato, MD, MRes, PhD – Imperial College London
Bruno Sangro, MD – Clinica Universidad de Navarra-Instituto de Investigación Sanitaria de Navarra (IDISNA)
Roberto I. Troisi, MD – Federico II University Naples
Andrea Wilson Woods, MFA – Blue Faery: The Adrienne Wilson Liver Cancer Association,
Thomas Yau, MD, MBBS, MRCP, FRCP, FHKCP, FHKAM – The University of Hong Kong,
Andrew X. Zhu, MD, PhD – Massachusetts General Hospital
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org